Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) EBIT Margin (2020 - 2025)

Historic EBIT Margin for Harmony Biosciences Holdings (HRMY) over the last 6 years, with Q3 2025 value amounting to 27.35%.

  • Harmony Biosciences Holdings' EBIT Margin fell 58200.0% to 27.35% in Q3 2025 from the same period last year, while for Sep 2025 it was 27.32%, marking a year-over-year increase of 16100.0%. This contributed to the annual value of 26.7% for FY2024, which is 62900.0% down from last year.
  • Latest data reveals that Harmony Biosciences Holdings reported EBIT Margin of 27.35% as of Q3 2025, which was down 58200.0% from 24.03% recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' EBIT Margin ranged from a high of 40.25% in Q3 2023 and a low of 10.15% during Q3 2022
  • Its 5-year average for EBIT Margin is 28.72%, with a median of 30.94% in 2022.
  • As far as peak fluctuations go, Harmony Biosciences Holdings' EBIT Margin skyrocketed by 727900bps in 2021, and later crashed by -225900bps in 2024.
  • Over the past 5 years, Harmony Biosciences Holdings' EBIT Margin (Quarter) stood at 31.39% in 2021, then grew by 18bps to 37.11% in 2022, then crashed by -36bps to 23.87% in 2023, then grew by 16bps to 27.69% in 2024, then decreased by -1bps to 27.35% in 2025.
  • Its last three reported values are 27.35% in Q3 2025, 24.03% for Q2 2025, and 30.45% during Q1 2025.